This site may require a log-in in the near future. We are constantly being swamped by AI agents. If they continue to take down the site, we will be changing to requiring logins to access any item.

🍽️ phenylpropanolamine hydrochloride,(prescription)

AI Engines For more Details: Perplexity  Kagi Labs  You 

  1. Decongestant: PPA has been used as a nasal decongestant to relieve symptoms associated with nasal congestion, sinus congestion, and allergies. It works by constricting blood vessels in the nasal mucosa, thereby reducing swelling and congestion.

  2. Appetite Suppressant: PPA has been included in some weight loss and appetite suppressant products. It acts centrally to decrease appetite and promote weight loss, although its efficacy for this purpose is controversial.

  3. Hemorrhagic Stroke: One of the most significant health impacts associated with phenylpropanolamine hydrochloride is its association with an increased risk of hemorrhagic stroke (bleeding in the brain), particularly in young women. This risk led to regulatory actions in many countries, including the withdrawal of PPA-containing products from the market.

  4. Cardiovascular Effects: PPA is a sympathomimetic agent, meaning it mimics the actions of the sympathetic nervous system. It can increase heart rate and blood pressure, which may be problematic in individuals with cardiovascular diseases or hypertension.

  5. Central Nervous System Stimulation: PPA can have stimulant effects on the central nervous system, leading to symptoms such as restlessness, insomnia, anxiety, and tremors.

  6. Psychiatric Effects: In some individuals, PPA may exacerbate or precipitate psychiatric symptoms such as agitation, psychosis, or mood disturbances.

  7. Urinary Effects: PPA can act as a urinary tract stimulant, potentially leading to urinary retention or difficulty urinating in susceptible individuals.

  8. Drug Interactions: PPA may interact with other medications, including monoamine oxidase inhibitors (MAOIs) and selective serotonin reuptake inhibitors (SSRIs), leading to potentially serious adverse effects such as serotonin syndrome.

  9. Withdrawal from Market: Due to safety concerns, particularly the association with hemorrhagic stroke, many regulatory agencies worldwide have banned or restricted the use of PPA in pharmaceutical products.

  10. Other Adverse Effects: PPA may also cause other adverse effects such as gastrointestinal disturbances (e.g., nausea, vomiting, diarrhea), dizziness, headache, and allergic reactions.

;

Check for interactions on Supp.AI   |   📚 PubMed Citations

⚗️ Compensation for antibiotic usage

Data Contradictions — Limits of Certainity

Impacted of phenylpropanolamine hydrochloride,(prescription) On Probiotics

Rank Probiotic Impact
species Lacticaseibacillus paracasei Reduces
species Parabacteroides distasonis Reduces

Bacteria Impacted by phenylpropanolamine hydrochloride,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

🧙?

📓 Direct Citations 👪👶 Indirect Citations Taxonomy Rank Effect
0 1 Parabacteroides genus Decreases
0 1 Ruminococcus genus Decreases
0 1 Bacteroides genus Decreases
0 1 Coprococcus genus Decreases
0 1 Fusobacterium genus Decreases
0 1 Streptococcus genus Decreases
0 1 Lacticaseibacillus genus Decreases
1 0 Lacticaseibacillus paracasei species Decreases
1 0 Streptococcus salivarius species Decreases
1 0 Ruminococcus bromii species Decreases
1 0 Fusobacterium nucleatum species Decreases
1 0 Coprococcus comes species Decreases
1 0 Parabacteroides distasonis species Decreases
1 0 Bacteroides xylanisolvens species Decreases
0 1 Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases
0 1 Fusobacterium nucleatum subsp. nucleatum subspecies Decreases
0 1 Lacticaseibacillus paracasei subsp. tolerans subspecies Decreases

Impact of phenylpropanolamine hydrochloride,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Acne 0.6 0.6
ADHD 1.3 0.3 3.33
Age-Related Macular Degeneration and Glaucoma 0.4 -0.4
Allergic Rhinitis (Hay Fever) 1.3 0.3 3.33
Allergies 1.4 1.2 0.17
Allergy to milk products 0.9 0.7 0.29
Alopecia (Hair Loss) 0.1 0.1
Alzheimer's disease 1.6 1.2 0.33
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.6 0.3 1
Ankylosing spondylitis 0.6 0.9 -0.5
Anorexia Nervosa 1 0.9 0.11
Antiphospholipid syndrome (APS) 0.3 0.3
Asthma 1.5 0.6 1.5
Atherosclerosis 0.9 0.3 2
Atrial fibrillation 1.6 0.7 1.29
Autism 1.9 1.9 0
Autoimmune Disease 0.3 0.3
Barrett esophagus cancer 0.3 0.3 0
benign prostatic hyperplasia 0.3 -0.3
Biofilm 0.6 0.6
Bipolar Disorder 1 0.6 0.67
Brain Trauma 0.3 0.6 -1
Breast Cancer 0.6 0.3 1
Cancer (General) 0.3 0.6 -1
Carcinoma 1.9 1 0.9
Celiac Disease 0.6 1 -0.67
Cerebral Palsy 0.6 0.6 0
Chronic Fatigue Syndrome 1.5 1.4 0.07
Chronic Kidney Disease 0.7 0.3 1.33
Chronic Lyme 0.3 -0.3
Chronic Obstructive Pulmonary Disease (COPD) 1.5 0.9 0.67
Chronic Urticaria (Hives) 0.3 0.3
Coagulation / Micro clot triggering bacteria 0.7 0.6 0.17
Cognitive Function 1.3 0.3 3.33
Colorectal Cancer 2.5 0.6 3.17
Constipation 0.6 0.7 -0.17
Coronary artery disease 0.6 0.6 0
COVID-19 1.6 2.1 -0.31
Crohn's Disease 2.3 1.6 0.44
Cushing's Syndrome (hypercortisolism) 0.3 -0.3
cystic fibrosis 0.3 -0.3
deep vein thrombosis 0.9 0.9 0
Denture Wearers Oral Shifts 1.2 1.2
Depression 2.5 2.4 0.04
Dermatomyositis 0.3 0.3
Eczema 0.6 0.9 -0.5
Endometriosis 1.3 0.6 1.17
Eosinophilic Esophagitis 0.3 0.3 0
Epilepsy 0.9 0.7 0.29
erectile dysfunction 0.6 0.6
Fibromyalgia 0.4 0.9 -1.25
Functional constipation / chronic idiopathic constipation 1.6 1.3 0.23
gallstone disease (gsd) 0.7 0.3 1.33
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.6 0.3 1
Generalized anxiety disorder 1.2 0.9 0.33
Glioblastoma 0.3 -0.3
Gout 1.2 0.6 1
Graves' disease 1 1.2 -0.2
Gulf War Syndrome 0.6 0.6
Halitosis 1.2 0.3 3
Hashimoto's thyroiditis 0.9 0.3 2
Heart Failure 1.9 0.3 5.33
hemorrhagic stroke 0.7 0.7
Hidradenitis Suppurativa 0.9 0.9
High Histamine/low DAO 0.3 -0.3
hyperglycemia 0.6 0.7 -0.17
hypertension (High Blood Pressure 1.3 1.2 0.08
Hypothyroidism 0.3 0.3 0
Hypoxia 0.7 0.7
IgA nephropathy (IgAN) 1.6 1.6
Inflammatory Bowel Disease 2.2 1.9 0.16
Insomnia 1.8 0.9 1
Intelligence 0.6 0.6
Intracranial aneurysms 1.3 0.3 3.33
Irritable Bowel Syndrome 1.2 1.6 -0.33
ischemic stroke 1.3 0.3 3.33
Liver Cirrhosis 2.5 1.5 0.67
Long COVID 1.5 1.9 -0.27
Low bone mineral density 0.3 -0.3
Lung Cancer 0.3 -0.3
Mast Cell Issues / mastitis 0.6 0.6 0
ME/CFS with IBS 0.3 0.5 -0.67
ME/CFS without IBS 0.3 0.3 0
membranous nephropathy 0.3 0.3
Menopause 0.3 0.3
Metabolic Syndrome 1.9 1.9 0
Mood Disorders 2.5 2.4 0.04
multiple chemical sensitivity [MCS] 0.9 0.9
Multiple Sclerosis 2.2 1.6 0.38
Multiple system atrophy (MSA) 0.3 -0.3
myasthenia gravis 0.3 0.3
neuropathic pain 0.7 -0.7
Neuropathy (all types) 0.3 0.7 -1.33
neuropsychiatric disorders (PANDAS, PANS) 0.3 0.3
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 1.2 0.9 0.33
NonCeliac Gluten Sensitivity 0.3 0.3 0
Obesity 1.9 3.4 -0.79
obsessive-compulsive disorder 1.4 0.9 0.56
Osteoarthritis 0.6 0.9 -0.5
Osteoporosis 0.6 0.6 0
pancreatic cancer 0.9 0.6 0.5
Parkinson's Disease 2.2 1.8 0.22
Polycystic ovary syndrome 2.3 1.2 0.92
Postural orthostatic tachycardia syndrome 0.3 -0.3
Premenstrual dysphoric disorder 0.4 -0.4
primary biliary cholangitis 0.3 0.6 -1
Primary sclerosing cholangitis 1.3 1.1 0.18
Psoriasis 0.6 1.1 -0.83
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 2.3 0.9 1.56
Rosacea 0.3 0.3
Schizophrenia 1.9 1.3 0.46
scoliosis 0.3 0.3 0
Sjögren syndrome 0.7 0.7 0
Sleep Apnea 0.9 0.9 0
Slow gastric motility / Gastroparesis 0.6 0.6
Small Intestinal Bacterial Overgrowth (SIBO) 1.2 1.2
Stress / posttraumatic stress disorder 1 1 0
Systemic Lupus Erythematosus 1.6 0.3 4.33
Tic Disorder 0.6 0.6
Tourette syndrome 0.3 0.3 0
Type 1 Diabetes 1.2 0.9 0.33
Type 2 Diabetes 2.2 1.9 0.16
Ulcerative colitis 1.4 1.3 0.08
Unhealthy Ageing 1.5 0.7 1.14
Vitiligo 1.3 0.6 1.17

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.   Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA   Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.   Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.   Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]